Jim Simons Biotechnology

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
KPTI Karyopharm Therapeutics Inc.	$332M	$817,000 0.0% of portfolio	1,202,590	Q4 2024 Reduced 3.13%
PRLD Prelude Therapeutics Inc	$29.1M	$805,000 0.0% of portfolio	634,500	Q4 2024 Added 222.24%
VYGR Voyager Therapeutics, Inc.	$141M	$793,000 0.0% of portfolio	139,900	Q4 2024 Reduced 49.8%
ANTX An2 Therapeutics, Inc.	$27M	$788,000 0.0% of portfolio	579,773	Q4 2024 Added 36.8%
PASG Passage Bio, Inc.	$20.7M	$787,000 0.0% of portfolio	1,381,476	Q4 2024 Reduced 0.82%
TARA Protara Therapeutics, Inc.	$51.6M	$747,000 0.0% of portfolio	142,300	Q4 2024 Reduced 57.74%
CLSD Clearside Biomedical, Inc.	$57.2M	$721,000 0.0% of portfolio	721,789	Q4 2024 Reduced 3.1%
FGEN Fibrogen Inc	$29.1M	$720,000 0.0% of portfolio	1,358,712	Q4 2024 Added 80.41%
VRNA Verona Pharma PLC	$3.82B	$719,000 0.0% of portfolio	15,500	Q4 2024 New
NUVL Nuvalent, Inc.	$3.14B	$712,000 0.0% of portfolio	9,100	Q4 2024 New
ICCC Immucell Corp	$38.8M	$705,000 0.0% of portfolio	136,989	Q4 2024 Reduced 8.36%
AURA Aura Biosciences, Inc.	$186M	$688,000 0.0% of portfolio	83,700	Q4 2024 Added 489.44%
CRTX Cortexyme, Inc.	$70.5M	$674,000 0.0% of portfolio	523,050	Q4 2024 Added 0.09%
FATE Fate Therapeutics Inc	$82.5M	$624,000 0.0% of portfolio	378,619	Q4 2024 Added 4.41%
ACHL Achilles Therapeutics PLC	$60.3M	$623,000 0.0% of portfolio	547,233	Q4 2024 Reduced 14.24%
VIGL Vigil Neuroscience, Inc.	$54M	$617,000 0.0% of portfolio	367,300	Q4 2024 Added 698.48%
ELDN Eledon Pharmaceuticals, Inc.	$46.1M	$601,000 0.0% of portfolio	147,173	Q4 2024 Added 8.32%
VOR Vor Biopharma Inc.	$28.5M	$587,000 0.0% of portfolio	529,500	Q4 2024 Reduced 29.96%
RAPT Rapt Therapeutics, Inc.	$36.2M	$584,000 0.0% of portfolio	369,736	Q4 2024 Added 25.5%
AKRO Akero Therapeutics, Inc.	$1.98B	$578,000 0.0% of portfolio	20,800	Q4 2024 New
BEAM Beam Therapeutics Inc.	$1.56B	$568,000 0.0% of portfolio	22,907	Q4 2024 New
IMUX Immunic, Inc.	$36.7M	$566,000 0.0% of portfolio	566,623	Q4 2024 Added 45.63%
ADGI Adagio Therapeutics, Inc.	$505M	$553,000 0.0% of portfolio	167,200	Q4 2024 New
IKNA Ikena Oncology, Inc.	$47.9M	$541,000 0.0% of portfolio	330,200	Q4 2024 Reduced 17.57%
XENE Xenon Pharmaceuticals Inc.	$2.13B	$537,000 0.0% of portfolio	13,700	Q4 2024 Reduced 68.86%
SANA Sana Biotechnology, Inc.	$325M	$521,000 0.0% of portfolio	319,818	Q4 2024 Added 1,838.29%
WVE Wave Life Sciences Ltd.	$748M	$513,000 0.0% of portfolio	41,520	Q4 2024 Reduced 60.28%
CABA Cabaletta Bio, Inc.	$45M	$506,000 0.0% of portfolio	230,161	Q4 2024 New
ABEO Abeona Therapeutics Inc.	$29.6M	$495,000 0.0% of portfolio	89,237	Q4 2024 Reduced 33.54%
BCAB Bio Atla, Inc.	$13.4M	$489,000 0.0% of portfolio	829,596	Q4 2024 Added 62.22%
IGMS Igm Biosciences, Inc.	$35.9M	$463,000 0.0% of portfolio	75,800	Q4 2024 Added 13.98%
RPTX Repare Therapeutics Inc.	$44M	$455,000 0.0% of portfolio	347,460	Q4 2024 Reduced 23.42%
PYXS Pyxis Oncology, Inc.	$37.2M	$454,000 0.0% of portfolio	293,354	Q4 2024 Added 82.96%
ABOS Acumen Pharmaceuticals, Inc.	$48.2M	$442,000 0.0% of portfolio	257,213	Q4 2024 Reduced 15.97%
RZLT Rezolute, Inc.	$114M	$427,000 0.0% of portfolio	89,700	Q4 2024 Reduced 67.77%
TRVI Trevi Therapeutics, Inc.	$379M	$427,000 0.0% of portfolio	100,400	Q4 2024 Added 42.01%
RLYB Rallybio Corp	$20.6M	$423,000 0.0% of portfolio	441,318	Q4 2024 Added 9.32%
XOMA Xoma Corp	$233M	$423,000 0.0% of portfolio	16,100	Q4 2024 Added 89.84%
NAUT Nautilus Biotechnology, Inc.	$111M	$420,000 0.0% of portfolio	250,221	Q4 2024 Added 61.75%
TYRA Tyra Biosciences, Inc.	$410M	$404,000 0.0% of portfolio	29,100	Q4 2024 New
CMPX Compass Therapeutics, Inc.	$202M	$403,000 0.0% of portfolio	278,600	Q4 2024 Added 25.16%
NXTC Next Cure, Inc.	$14.2M	$399,000 0.0% of portfolio	519,300	Q4 2024 Added 27.91%
MNOV Medicinova Inc	$72.6M	$380,000 0.0% of portfolio	181,300	Q4 2024 Reduced 2.84%
ORMP Oramed Pharmaceuticals Inc.	$90.1M	$367,000 0.0% of portfolio	151,808	Q4 2024 Reduced 38.11%
PLRX Pliant Therapeutics, Inc.	$71.6M	$366,000 0.0% of portfolio	27,800	Q4 2024 Reduced 72.53%
CNTX Context Therapeutics Inc.	$10.5M	$335,000 0.0% of portfolio	338,435	Q4 2024 Added 412.78%
NERV Minerva Neurosciences, Inc.	$9.61M	$284,000 0.0% of portfolio	128,100	Q4 2024 Reduced 18.51%
XLO Xilio Therapeutics, Inc.	$20.6M	$284,000 0.0% of portfolio	296,617	Q4 2024 Added 11.38%
LTRN Lantern Pharma Inc.	$38.4M	$277,000 0.0% of portfolio	87,300	Q4 2024 Added 3.93%
RCUS Arcus Biosciences, Inc.	$590M	$275,000 0.0% of portfolio	18,500	Q4 2024 Reduced 89.94%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account